TORONTO, April 23, 2018 (GLOBE NEWSWIRE) — Canada House Wellness Group Inc. (CSE:CHV) (“Canada House” or the “Company”) is pleased to announce that:

Its Abba Medix Corp subsidiary has received from Health Canada its License to Produce Cannabis Oil; and It will begin its cannabis cultivation on 1st May 2018.

Abba Medix President, Riley McGee asserted, “Receiving our License to Produce Cannabis Oil allows us to accelerate our recently announced joint venture with Nutritional High International Inc. to produce extract-based products approved for the Canadian market.” “I’d like to commend our Abba Medix team on the hard work required to obtain this important license,” he added.

The Company is also pleased to advise its shareholders that it has now received all of the required Health Canada approvals to begin cannabis cultivation on 1st May 2018 at our Abba Medix Pickering, ON facility.

Canada House Wellness Group Inc.
Canada House is the parent company of Marijuana for Trauma Inc., Knalysis Technologies and Abba Medix Corp. The Company’s goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully integrated cannabis therapy company. For more information please visit or

For further information, please contact:
Boom Capital Markets
Steve Low

Canada House Wellness Group, Inc.
Larry Bortles

Cautionary Statement Regarding Forward‐Looking Information. Certain statements within this news release pertaining to the Company constitute “forward‐looking statements”, within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and/or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are “forward‐looking statements”. Such “forward‐looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward‐looking statements include, but are not limited to, statements with respect to the anticipated effects of the financing, regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, competition and other risks affecting the Company in particular and the medical marijuana industry generally, including those set out in the Company’s public disclosure record. The Company assumes no responsibility to update or revise forward‐looking information to reflect new events or circumstances unless required by law.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.